Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857124 | 0.81 | ESR1 (0.61) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18604566 | 0.80 | TRPA1 (0.46) | ACHETRPA1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL3313456 | 0.77 | ALDH1A1 (0.42) | TSHRACHEALDH1A1KDM4EMAPT | |
| SCHEMBL27928670 | 0.76 | ESR1 (0.32) | ACHEESR1ESR2ARNR1H2 | |
| SCHEMBL3824007 | 0.75 | ALDH1A1 (0.40) | TSHRACHEALDH1A1KDM4EMAPT | |
| SCHEMBL16558528 | 0.74 | KDM1A (0.37) | ACHEALOX15ESR1ESR2AR | |
| SCHEMBL20089237 | 0.73 | ACHE (0.33) | ACHENR1H2NR1H3 | |
| SCHEMBL13318430 | 0.71 | ESR1 (0.36) | ACHETRPA1ESR1ESR2AR | |
| SCHEMBL14359572 | 0.71 | SHBG (0.38) | TSHRACHEALDH1A1KDM4EPKM | |
| SCHEMBL9726921 | 0.70 | SMN1; SMN2 (0.42) | TSHRACHEALDH1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261918-A1 | Silicon Compounds and Their Use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| EP-1644385-B1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| CN-1823076-A | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| EP-1644385-A1 | SILICON COMPOUNDS AND THEIR USE | Paradigm Therapeutics Limited (GB) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005005442-A1 | SILICON COMPOUNDS AND THEIR USE | PARADIGM THERAPEUTICS LTD. (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070110708-A1 | Silicon compounds and their use | SOST, SMAD3, SMAD2 | TSHR 4491/4885CASP1 695/4885ACHE 650/4885 |
| US-20080261918-A1 | Silicon Compounds and Their Use | SOST, SIK2, SCLY | TSHR 3872/4885CASP1 1467/4885ACHE 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.